Celgene Snags Cancer Treatment Co. Avila For $350M
Celgene Corp. has paid $350 million in cash to acquire Avila Therapeutics Inc., a biotechnology company whose potential cancer treatment has shown promise in clinical studies, Celgene said Thursday....To view the full article, register now.
Already a subscriber? Click here to view full article